Previsão
| Comprar |
1 |
| Manter |
0 |
| Vender |
0 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
SIGA Technologies pays special dividend of $0.60 per share
The board of directors of SIGA Technologies has approved a cash dividend of $0.60 per common share, payable on April 23, 2026 to shareholders of record at the close of trading on April 7, 2026. The payout matches the special dividend announced in April 2025 and, according to InvestingPro, represents a yield of about 12%. The company shows a high liquidity ratio (current ratio 11.83), while the stock, at $4.81, is trading near its 52-week low and has fallen roughly 46% over the past six months. SIGA Technologies is in the commercialization phase and focuses on drugs for the treatment and prevention of infectious diseases, particularly orthopoxviruses. » Mais em de.investing.com
SIGA Technologies posts annual profit of $23 million despite quarterly loss
SIGA Technologies reported 2025 annual revenue of $95 million and a net profit of $23 million, with a cash balance of $155 million and no debt. However, in the fourth quarter the company posted a loss per share of -$0.08, highlighting quarterly volatility due to irregular government procurement. Investor reactions were mixed: the stock fell in after-hours trading but recovered in pre-market trading. Remaining risks include regulatory uncertainty in Europe for the Mpox indication and strong dependence on U.S. government contracts. » Mais em de.investing.com
SIGA Technologies reports strong 2025 results and remains debt-free
SIGA Technologies recorded total revenue of $95 million in 2025, including $88 million in product revenue, and net income of $23 million (earnings per share $0.32). The company holds $155 million in cash, is debt-free, and delivered TPOXX worth $79 million to the U.S. government. Outstanding government orders of $26 million for 2026, plus $27 million in grants for pediatric and intravenous formulations, underpin the optimistic outlook. » Mais em de.investing.com
SIGA Technologies: stock falls despite strong revenue growth in third quarter
SIGA Technologies reported product revenues of $86 million for the first nine months (prior year $54 million), driven by strong TPOXX sales. The company holds $172 million in cash and is debt-free; net income for the nine months amounted to $29 million. The stock fell 3.08% to $8.07 in after-hours trading following the release of the figures. SIGA plans an FDA filing for TPOXX for post-exposure prophylaxis, is working on a pediatric formulation and expects international sales in 2026, but sees risks from procurement delays and regulatory hurdles. » Mais em de.investing.com
SIGA Technologies reports stable quarterly results and remains financially solid
SIGA Technologies posted stable revenues of $79 million and earnings per share of $0.49 in the second quarter of 2025, while the stock price remained nearly unchanged. The company remains debt-free with a cash balance of $182 million and plans to submit new approval applications for its TPOXX products. However, international business development remains volatile, and reliance on US government contracts poses risks. » Mais em de.investing.com
Dividendos históricos Dividendos
Todos os indicadores de dividendos Todos os indicadoresEm 2026, SIGA Technologies já distribuiu € 0,51 em dividendos. A última distribuição ocorreu em abril.
Dados financeiros
No último trimestre, SIGA Technologies registou receitas de € 1,16 mi e um ganho líquido de -€ 2,55 mi
| (EUR) | setembro de 2026 | YoY |
|---|---|---|
| Receitas | 1,16 mi | 47,92% |
| Ganho bruto | 654,46 mil | 52,53% |
| Ganho líquido | -2,55 mi | 52,91% |
| EBITDA | -4,84 mi | 30,85% |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 156,84 mi |
Número de ações | 71,86 mi |
Máximo/mínimo de 52 semanas | € 6,48 - € 2,16 |
Rentabilidade de dividendos | 19,83% |
Dividendos TTM | € 0,51 |
Beta | 1,02 |
PER (PE Ratio) | 374,22 |
PEG (PEG Ratio) | -3,43 |
P/VC (PB Ratio) | 1,05 |
P/V (PS Ratio) | 3,29 |
Perfil da empresa
A SIGA Technologies, Inc., uma empresa farmacêutica em fase comercial, concentra-se nos mercados de segurança sanitária e doenças infecciosas nos Estados Unidos. O seu produto principal é o TPOXX, um antiviral de administração oral para o tratamento da varíola humana causada pelo vírus variola. A SIGA Technologies, Inc. tem uma parceria estratégica com a Cipla Therapeutics para garantir inovação sustentada e acesso a medicamentos antibacterianos, sobretudo contra ameaças biológicas. A empresa foi constituída em 1995 e tem sede em Nova Iorque, Nova Iorque.
| Nome | SIGA Technologies |
| CEO | Diem Nguyen |
| Sede | New York City,
ny EUA |
| Site | |
| Setor | Materiais básicos |
| Indústria | Produtos químicos |
| Entrada em bolsa | 10/09/1997 |
| Colaboradores | 49 |
Análise aprofundada
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | SIGA |